ABSTRACT
Purpose: To evaluate the efficacy and toxicity of combination chemotherapy with paclitaxel and oxaliplatin (two new drugs) in patients with locally advanced and(or) metastatic gastric adenocarcinoma ( M/AGC). Methods: Between May 2001 and May 2002, 30 patients (22 male and 8 female) with a median age of 58 years (range35-80) were consecutively enrolled in this study. Oxaliplatin and paclitaxel were administered as a two-hour infusion every one or two weeks, respectively, and DDP or FUDR were infused in abdominal cavity every one week. Results: Thirty patients were evaluable for activity, with 2 complete and 17 partial responses, objective response rate( RR): 63% ( 95% CI: 46% -80%). Twenty-three of thirty patients (77%) experienced WHO grade Ⅰ-Ⅳ bone marrow suppression, which was the most common and serious toxicity. WHO Grade Ⅰ-Ⅲ side effect ( non-hematological toxicity) of gastrointestinal tract, liver, peripheral neuropathy, kidney , mucositis and heart occurred in 40%, 30%, 13%, 10%, 10% and 7% of patients, respectively. No patients withdrew because of treatment-related toxicity. Conclusions: Our data suggest that the combination of paclitaxel and oxaliplatin has promising therapeutic activity in patients with advanced gastric cancer. This regimen shows good efficacy and an acceptable safety profile in M/AGC patients, and may prove to be a suitable alternative regimen in this indication, especially for the patients with bad function of the heart , liver and kidney or old, physically weak patients.
ABSTRACT
Purpose:To explore the relationship between the infection of Helicobacter pylori (Hp), cell apoptosis and the expression of EGFR,VEGF in gastric mucosa and the gastrocarcinogenesis in Changle city, where has a high incidence of gastric carcinomas. Methods:The status of Hp infection was detected by the serum Hp antibody detection and the Hp special staining. The in situ TUNEL method was used in the apoptosis index (AI) detection. The immunohistochemical method (with S P kit) was used in the detection of the EGFR, VEGF expression. Results:The present infection rate of Hp in the series of the gastrocarcinogenesis was 74.4%, and was highest in the objects with chronic atrophic gastritis and/or intestinal metaplasia (CAG IM, 92.5%) . The AI was highest in the subjects with CAG IM, and lowest in the subjects with chronic superficial gastritis (CSG), the data were 0.357 and 0.179 respectively. The expression rate of EGFR was highest in the subjects with CAG IM, and lowest in the subjects with CSG, the data were 51.35% and 75% respectively. The expression rate of VEGF was highest in the subjects with GC, and lowest in the subjects with AH, the data were 65% and 35% respectively ( P